We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Stock Moves -0.23%: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Abbott (ABT - Free Report) standing at $131.63, reflecting a -0.23% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. Elsewhere, the Dow lost 3.98%, while the tech-heavy Nasdaq lost 5.97%.
The maker of infant formula, medical devices and drugs's shares have seen a decrease of 4.2% over the last month, surpassing the Medical sector's loss of 4.6% and the S&P 500's loss of 4.7%.
The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. The company is scheduled to release its earnings on April 16, 2025. It is anticipated that the company will report an EPS of $1.07, marking a 9.18% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $10.42 billion, indicating a 4.54% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.15 per share and a revenue of $44.42 billion, indicating changes of +10.28% and +5.9%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.04% rise in the Zacks Consensus EPS estimate. At present, Abbott boasts a Zacks Rank of #2 (Buy).
With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 25.63. This represents a premium compared to its industry's average Forward P/E of 18.06.
It's also important to note that ABT currently trades at a PEG ratio of 2.46. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Products industry currently had an average PEG ratio of 2.12 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 168, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Stock Moves -0.23%: What You Should Know
The most recent trading session ended with Abbott (ABT - Free Report) standing at $131.63, reflecting a -0.23% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. Elsewhere, the Dow lost 3.98%, while the tech-heavy Nasdaq lost 5.97%.
The maker of infant formula, medical devices and drugs's shares have seen a decrease of 4.2% over the last month, surpassing the Medical sector's loss of 4.6% and the S&P 500's loss of 4.7%.
The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. The company is scheduled to release its earnings on April 16, 2025. It is anticipated that the company will report an EPS of $1.07, marking a 9.18% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $10.42 billion, indicating a 4.54% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.15 per share and a revenue of $44.42 billion, indicating changes of +10.28% and +5.9%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.04% rise in the Zacks Consensus EPS estimate. At present, Abbott boasts a Zacks Rank of #2 (Buy).
With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 25.63. This represents a premium compared to its industry's average Forward P/E of 18.06.
It's also important to note that ABT currently trades at a PEG ratio of 2.46. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Products industry currently had an average PEG ratio of 2.12 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 168, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.